General Information of API (ID: D00991)
Name
Deferoxamine mesylate
Synonyms    Click to Show/Hide the Synonyms of This API
Deferoxamine mesylate; 138-14-7; Desferrioxamine B mesylate; Desferal; Deferoxamine mesilate; Desferrioxamine mesylate; Deferoxamine B mesylate; Deferoxamine (mesylate); Deferoxamine methanesulfonate; Desferal mesylate; UNII-V9TKO7EO6K; Desferioxamine mesylate; V9TKO7EO6K; DESFERRIOXAMINE MESILATE; MLS000028713; Desferrioxamine B mesylate;DFOM; MFCD00058605; 138-14-7 (MESYLATE); NCGC00017021-01; CAS-138-14-7; Desferal (TN); Deferoxamine-D8 mesylate; Deferoxamine mesylate salt; DSSTox_CID_17649; DSSTox_RID_79351; DSSTox_GSID_37649; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide;methanesulfonic acid; Desferal methanesulfonate; DFX mesylate; CHEBI:31460; N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy-butanediamide, monomethanesulfonate; NSC644468; SR-01000695424; SMR000058548; EINECS 205-314-3; Ba 33122; 138D147; Desferrioxamine mesylate salt; CCRIS 8311; Deferoxamine methanesulfonate salt; C26H52N6O11S; Deferoxamine mesylate [USAN:USP]; Prestwick_988; Deforoxamine B mesylate; CHEMBL1234; Deferoxamine mesylate, 95%; Deferoxamine mesylate (USP); N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid monomethanesulfonate (salt); SCHEMBL119982; SPECTRUM1500224; Deferoxamine mesilate (JP17); DTXSID6037649; HMS500E04; HMS1570A12; HMS1920C16; HMS2091K08; HMS2097A12; HMS2234H23; HMS3714A12; Pharmakon1600-01500224; BCP31290; EX-A4085; HY-B0988; Tox21_110741; CCG-39770; NSC756718; s5742; AKOS026750165; Tox21_110741_1; CS-4479; NSC-644468; NSC-756718; NCGC00017021-02; NCGC00017021-03; NCGC00094640-01; NCGC00094640-02; NCGC00178802-06; Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-, monomethanesulfonate; Deferoxamine Mesylate - CAS 138-14-7; Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)-, monomethanesulfonate (salt); AB0035971; DB-042415; FT-0603121; Y0490; D01186; A807339; SR-01000695424-2; SR-01000695424-3; SR-01000695424-4; Deferoxamine mesylate salt, powder, >=92.5% (TLC); Q27114315; Desferrioxamine B mesylate; DFOM;Desferrioxamine mesylate; Deferoxamine mesylate salt, European Pharmacopoeia (EP) Reference Standard; Deferoxamine mesylate, United States Pharmacopeia (USP) Reference Standard; Deferoxamine for system suitability, European Pharmacopoeia (EP) Reference Standard; N'-(5-azanylpentyl)-N-[5-[[4-[5-[ethanoyl(oxidanyl)amino]pentylamino]-4-oxidanylidene-butanoyl]-oxidanyl-amino]pentyl]-N'-oxidanyl-butanediamide; methanesulfonic acid; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccinamide methanesulfonate (salt); N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-1,4-dioxobutyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide; methanesulfonic acid; N1-(5-aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-(5-(N-hydroxyacetamido)pentylamino)-4-oxobutanamido)pentyl)succinamide methanesulfonate; N4-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxybutanediamide methanesulfonate; N4-[5-[[4-5-(Acetylhydroxyamino)pentyl]-1,4-dioxobutyl]hydroxyaminopentyl-N1-(5-aminopentyl)-N1-hydroxybutanediamide methanesulfonate
Clinical Status
Approved
PubChem CID
62881
Formula
C26H52N6O11S
Canonical SMILES
CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O.CS(=O)(=O)O
InChI
1S/C25H48N6O8.CH4O3S/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26;1-5(2,3)4/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34);1H3,(H,2,3,4)
InChIKey
IDDIJAWJANBQLJ-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=62881"></iframe>
3D MOL is unavailable 2D MOL
Physicochemical Properties Molecular Weight 656.8 Topological Polar Surface Area 269
XlogP N.A. Complexity 832
Heavy Atom Count 44 Rotatable Bond Count 23
Hydrogen Bond Donor Count 7 Hydrogen Bond Acceptor Count 12
Full List of Drug Formulations (DFMs) Containing This API
          Deferoxamine Mesylate 500mg lyophilized powder Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Water
                   Dosage Form Lyophilized Powder
                   Company Hospira

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.